YY1 and metabolic dysfunction-associated steatotic liver disease: Emerging evidence implicates YY1 as a key pathogenic factor in the development of metabolic disorders, including insulin resistance, obesity, T2D, and metabolic dysfunction-associated steatotic liver disease (MASLD) (79, 210).